MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) and Veru (NASDAQ:VERU – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for MoonLake Immunotherapeutics and Veru, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MoonLake Immunotherapeutics | 0 | 2 | 9 | 0 | 2.82 |
| Veru | 0 | 0 | 4 | 0 | 3.00 |
MoonLake Immunotherapeutics currently has a consensus target price of $80.45, suggesting a potential upside of 67.61%. Veru has a consensus target price of $4.00, suggesting a potential upside of 334.78%. Given Veru’s stronger consensus rating and higher possible upside, analysts clearly believe Veru is more favorable than MoonLake Immunotherapeutics.
Insider and Institutional Ownership
Earnings & Valuation
This table compares MoonLake Immunotherapeutics and Veru”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MoonLake Immunotherapeutics | N/A | N/A | -$36.01 million | ($0.75) | -64.00 |
| Veru | $14.09 million | 9.56 | -$93.15 million | ($0.34) | -2.71 |
MoonLake Immunotherapeutics has higher earnings, but lower revenue than Veru. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
MoonLake Immunotherapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Veru has a beta of -0.49, suggesting that its share price is 149% less volatile than the S&P 500.
Profitability
This table compares MoonLake Immunotherapeutics and Veru’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MoonLake Immunotherapeutics | N/A | -10.61% | -10.36% |
| Veru | -376.38% | -115.99% | -66.94% |
Summary
MoonLake Immunotherapeutics beats Veru on 7 of the 13 factors compared between the two stocks.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
About Veru
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
